Regal Investment Advisors LLC Acquires 597 Shares of GSK plc (NYSE:GSK)

Regal Investment Advisors LLC lifted its holdings in shares of GSK plc (NYSE:GSK) by 7.6% during the 4th quarter, Holdings Channel reports. The firm owned 8,503 shares of the pharmaceutical company’s stock after purchasing an additional 597 shares during the quarter. Regal Investment Advisors LLC’s holdings in GSK were worth $288,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Indiana Trust & Investment Management Co grew its stake in shares of GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust bought a new position in GSK in the fourth quarter worth approximately $26,000. ST Germain D J Co. Inc. grew its stake in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the period. Sierra Ocean LLC bought a new stake in shares of GSK during the fourth quarter valued at approximately $32,000. Finally, Parkside Financial Bank & Trust raised its position in shares of GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 818 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK stock opened at $35.92 on Friday. The business’s fifty day simple moving average is $37.44 and its 200 day simple moving average is $36.14. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The firm has a market capitalization of $74.10 billion, a P/E ratio of 22.59, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Investors of record on Friday, February 21st were paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.38%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, February 21st. GSK’s payout ratio is currently 100.63%.

Analyst Upgrades and Downgrades

GSK has been the subject of several research reports. BNP Paribas began coverage on shares of GSK in a research report on Tuesday. They issued a “neutral” rating and a $35.25 price target for the company. Morgan Stanley began coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.